AREC — Arecor Therapeutics Share Price
Last trade - 00:00- £35.99m
- £29.57m
- £4.57m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.86 | ||
| Price to Tang. Book | 5.9 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 8.04 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -89.71% | ||
| Return on Equity | -63.41% | ||
| Operating Margin | -200.63% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 1.1 | 1.7 | 1.16 | 2.4 | 4.57 | 7.47 | 11.33 | 27.64% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Arecor Therapeutics plc is a United Kingdom-based globally focused biopharmaceutical company. The Company, by applying its technology platform, Arestat, is developing an internal portfolio of products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver therapeutic products. Its portfolio includes AT247 - Ultra-Rapid Acting Insulin and AT278 - Ultra-Concentrated Ultra-Rapid Acting Insulin. Its lead product, AT247, is an Arestat enabled formulation of insulin designed to accelerate insulin absorption post injection, to enable effective management of blood glucose levels for people living with diabetes, particularly around difficult to manage mealtimes. The Company's AT278 is an ultra-concentrated novel formulation of ultra-rapid acting insulin. Its subsidiary, Tetris Pharma Ltd, has a portfolio of injectable products including Ogluo, which is a ready-to-use glucagon for emergency use to treat hypoglycemia.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- April 13th, 2021
- Public Since
- June 3rd, 2021
- No. of Employees
- 50
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 30,626,986
- Address
- Chesterford Research Park, SAFFRON WALDEN, CB10 1XL
- Web
- https://arecor.com/
- Phone
- +44 1223426060
- Auditors
- Grant Thornton UK LLP
Latest News for AREC
Upcoming Events for AREC
Arecor Therapeutics PLC Annual Shareholders Meeting
Half Year 2024 Arecor Therapeutics PLC Earnings Release
Similar to AREC
4Basebio
London Stock Exchange
Allergy Therapeutics
London Stock Exchange
Avacta
London Stock Exchange
Batm Advanced Communications
London Stock Exchange
Bioventix
London Stock Exchange
FAQ
As of Today at 19:20 UTC, shares in Arecor Therapeutics are trading at 120.00p. This share price information is delayed by 15 minutes.
Shares in Arecor Therapeutics last closed at 120.00p and the price had moved by -50% over the past 365 days. In terms of relative price strength the Arecor Therapeutics share price has underperformed the FTSE All Share Index by -54.87% over the past year.
The overall consensus recommendation for Arecor Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Arecor Therapeutics does not currently pay a dividend.
Arecor Therapeutics does not currently pay a dividend.
Arecor Therapeutics does not currently pay a dividend.
To buy shares in Arecor Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 120.00p, shares in Arecor Therapeutics had a market capitalisation of £36.75m.
Here are the trading details for Arecor Therapeutics:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: AREC
Based on an overall assessment of its quality, value and momentum Arecor Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Arecor Therapeutics is 459.00p. That is 282.5% above the last closing price of 120.00p.
Analysts covering Arecor Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -£0.00 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Arecor Therapeutics. Over the past six months, its share price has underperformed the FTSE All Share Index by -38.08%.
As of the last closing price of 120.00p, shares in Arecor Therapeutics were trading -26.74% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Arecor Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 120.00p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Arecor Therapeutics' directors